KaliVir Immunotherapeutics, LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From KaliVir Immunotherapeutics, LLC
Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.
Plus deals involving SELLAS/3D Medicines, Kyowa Kirin/InveniAI, JW/Voronoi, Y-mAbs/Takeda, Horizon Discovery/Sanyou, Sentinel Oncology/PharmaEngine